Methotrexate and rheumatoid arthritis associated interstitial lung disease
| Autor: | Kevin D. Deane, Eric L. Matteson, Leticia Kawano-Dourado, Yannick Allanore, René-Marc Flipo, Christophe Richez, Sébastien Ottaviani, David A. Schwartz, Karina Bonfiglioli, Montserrat I González-Pérez, Yurdagul Uzunhan, Gabriel Thabut, Jorge Rojas Serrano, Raphael Borie, Thierry Schaeverbeke, Benoit Wallaert, Ivan O. Rosas, Ramcés Falfán-Valencia, Lorenzo Cavagna, Marie-Elise Truchetet, Pascal Richette, Marco Sebastiani, Tracy J. Doyle, Emanuele Bozzalla Cassione, Gouri Koduri, Esther Ebstein, Jay H. Ryu, Lidwine Wemeau-Stervinou, Huguette Lioté, Dominique Valeyre, Pedro Rodríguez-Henriquez, Raphaël Porcher, Bruno Crestani, Jessica Lau, Steven Gazal, Marie-Christophe Boissier, Marie-Pierre Debray, Hilario Nunes, Mayra Mejía, Ivette Buendía-Roldán, Sylvain Marchand-Adam, Robert Vassallo, Andreina Teresa Manfredi, Nathalie Saidenberg-Kermanac’h, Joshua J. Solomon, Claire Dromer, Joyce S. Lee, Gloria Pérez-Rubio, Catherine Boileau, V. Michael Holers, Pierre-Antoine Juge, Marcio Valente Yamada Sawamura, Ronaldo Adib Kairalla, Caroline Kannengiesser, Philippe Dieudé |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
030203 arthritis & rheumatology
Pulmonary and Respiratory Medicine medicine.medical_specialty Extramural business.industry Diffuse lung disease respiratory system behavioral disciplines and activities Article respiratory tract diseases Arthritis Rheumatoid body regions 03 medical and health sciences Methotrexate 0302 clinical medicine Antirheumatic Agents Case-Control Studies Family medicine medicine Humans In patient 030212 general & internal medicine Lung Diseases Interstitial business Lung |
| Zdroj: | Eur Respir J |
| ISSN: | 1399-3003 0903-1936 |
| DOI: | 10.1183/13993003.00337-2020 |
| Popis: | Background: Methotrexate (MTX) is a key anchor drug for rheumatoid arthritis (RA) management. Its use has been associated with hypersensitivity pneumonitis and diffuse lung disease. Whether MTX exposure increases the risk of interstitial lung disease (ILD) in patients with RA is disputed. Objectives: We aimed to evaluate the association of antecedent MTX use with development of RA-ILD. Methods: Through a case-control study design with derivation and international validation samples, we examined the association of MTX exposure with ILD in 482 patients with RA-ILD and 741 patients with RA without ILD. Estimates were pooled over the different samples using meta-analysis techniques. Results: Analysis of the derivation sample revealed an inverse relationship between MTX exposure and RA-ILD (adjusted odds ratio [OR], 0.48; 95% confidence interval [CI], 0.25 to 0.92; P=0.028), which was confirmed in the validation samples (pooled adjusted OR, 0.39; 95% CI, 0.23 to 0.68; P Conclusion: Our results suggest that MTX is not a risk factor for RA-ILD and support a possible disease modifying effect of MTX on development of RA-ILD. Disclosure of Interests: Pierre-Antoine Juge: None declared, Joyce S. Lee Consultant of: Celgene, Genentech, Boehringer Ingelheim, Jessica Lau: None declared, Leticia Kawano: None declared, Jorge Rojas-Serrano: None declared, Marco Sebastiani: None declared, Gouri Koduri: None declared, Eric Matteson Grant/research support from: Pfizer, Consultant of: Boehringer Ingelheim, Gilead, TympoBio, Arena Pharmaceuticals, Speakers bureau: Simply Speaking, Karina Bonfiglioli Consultant of: Roche, Abbvie, Pfizer, Janssen and BMS, Marcio Sawamura: None declared, Ronaldo Kairalla: None declared, Lorenzo Cavagna: None declared, Emanuele Bozzalla Cassione: None declared, Andreina Manfredi: None declared, Mayra Mejia: None declared, Pedro Rodriguez Henriquez: None declared, Montserrat I. Gonzalez-Perez: None declared, Ramces Falfan-Valencia: None declared, Ivette Buendia-Roldan: None declared, Glora Perez-Rubio: None declared, Esther Ebstein Consultant of: BMS, Employee of: BMS, Steven Gazal: None declared, Raphael Borie Consultant of: Roche, Boehringer Ingelheim, Sebastien Ottaviani: None declared, Caroline Kannengiesser: None declared, Benoit Wallaert Consultant of: Roche, Boehringer Ingelheim, Yurdagul Uzunhan Consultant of: Roche, Boehringer Ingelheim,, Hilario Nunes: None declared, Dominique Valeyre Consultant of: Astra Zeneca, Roche, Boehringer Ingelheim, Nathalie Saidenberg Kermanac’h: None declared, marie-Christophe Boissier: None declared, Lidwine Wemeau Stervinou Consultant of: Roche, Janssen, BMS, Boehringer Ingelheim, Rene-Marc Flipo Speakers bureau: Novartis, Janssen, Lilly, Sylvain Marchand-Adam Consultant of: Roche, Novartis, Boehringer Ingelheim, Pascal Richette: None declared, Yannick Allanore Shareholder of: Sanofi, Roche, Consultant of: Actelion, Bayer, BMS, Boehringer Ingelheim, Inventiva, Sanofi, Claire Dromer: None declared, Marie-Elise Truchetet: None declared, Christophe Richez Consultant of: Abbvie, Amgen, Mylan, Pfizer, Sandoz and UCB., Thierry Schaeverbeke: None declared, Huguette Liote: None declared, Gabriel Thabut Employee of: Astra Zeneca, Kevin Deane Grant/research support from: Janssen, Consultant of: Inova, ThermoFisher, Janseen, BMS and Microdrop, Joshua Solomon: None declared, Tracy Doyle: None declared, Jay H. Ryu: None declared, Ivan O. Rosas Consultant of: Boehringer Ingelheim, Gerentech, Three Lakes Partners, V. Michael Holers Grant/research support from: Janssen, Celgene, and BMS, Catherine Boileau: None declared, Marie-Pierre Debray: None declared, Raphael Porcher: None declared, David A. Schwartz Consultant of: NuMedii, Robert Vassallo Shareholder of: Pfizer, BMS, SunPharma, Bruno Crestani Shareholder of: Apellis, Boehringer Inghelheim, Medillune, Roche, Consultant of: Boehringer Ingelhiem, Astra Zeneca, Roche, Sanofi, Philippe Dieude: None declared |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|